Biocardia announces clarification and next steps on its autologous cardiamp cell therapy programs

Sunnyvale, calif., sept. 06, 2023 (globe newswire) -- biocardia®, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced a clarification and next steps on its autologous cardiamp cell therapy programs.

BCDA Ratings Summary

BCDA Quant Ranking